" class="no-js "lang="en-US"> Oncology Archives - Page 2 of 43 - Medtech Alert
Thursday, March 30, 2023

Sort by:


Top Post

NHS Slashes Longest Elective and Cancer Patient Waiting Lists

The number of people waiting over 18 months for NHS care has fallen again despite […]

Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)

Incyte today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved […]

Novartis Trial Shows Benefit in Patients with Breast Cancer

Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III […]

Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer

Bayer further expands the global clinical development program for NUBEQA (darolutamide) in prostate cancer. The […]

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

Massive Bio, a private AI-enabled oncology startup that provides virtual and in-person concierge services for […]

Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing

Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1

Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has […]

Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution

Lunit, a leading global provider of AI-powered cancer solutions, today announced that its AI solution […]

China's First Personalized Neoantigen-Targeted Cancer Vaccine Receives NMPA's Clinical Trial Approval

According to the latest data released in the Clinical Trials Implied Approval section on the […]

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]

  1. Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Read more
  2. Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Read more
  3. Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Read more
  4. Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Read more
  5. Implantica Launches RefluxStop™ in Italy Read more